Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.50 |
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1865945 | 0.93 | ADRB2 (0.48) | ADRB2HRH3RORC | |
| SCHEMBL1865961 | 0.86 | OPRK1 (0.52) | ADRB2HRH3RORCGAA | |
| SCHEMBL12274214 | 0.85 | ADRB2 (0.52) | ADRB2HRH3RORC | |
| SCHEMBL13974451 | 0.84 | RORC (0.56) | ADRB2HRH3RORCGAASMN1; SMN2 | |
| SCHEMBL12273808 | 0.84 | UTS2R (0.44) | ADRB2RORC | |
| SCHEMBL1863758 | 0.83 | RORC (0.52) | RORCMEN1KMT2AGAA | |
| SCHEMBL1865570 | 0.83 | RORC (0.49) | RORCMEN1KMT2A | |
| SCHEMBL1866601 | 0.81 | RORC (0.50) | RORC | |
| SCHEMBL1868406 | 0.81 | ADRB2 (0.53) | ADRB2RORCPRKAA2 | |
| SCHEMBL12075912 | 0.80 | RORC (0.46) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108939-B2 | (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis | MERCK SHARP & DOHME B.V. (NL) | 2015-08-18 | — | — | US | disclosed |
| EP-2493855-B1 | (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis | MERCK SHARP & DOHME (NL) | 2014-02-26 | — | — | EP | disclosed |
| US-20120238574-A1 | (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | N.V. ORGANON (NL) | 2012-09-20 | — | — | US | disclosed |
| EP-2493855-A1 | (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | MSD Oss B.V. (NL) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051282-A1 | (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238574-A1 | (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | TGFB1, FPR1, TGFB2 | ADRB2 120/4885HRH3 1770/4885RORC 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.